Heron therapeutics shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and issued FY24 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $4 to $5.
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics' shares surged following the announcement of better-than-expected Q4 adjusted EPS results and optimistic FY24 revenue guidance. Additionally, Needham reaffirmed a Buy rating on HRTX and increased its price target from $4 to $5.
March 13, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Heron Therapeutics' stock price is likely to experience a short-term increase due to positive Q4 earnings, favorable FY24 revenue guidance, and an upgraded price target by Needham.
Positive earnings reports and optimistic future revenue guidance typically lead to an increase in stock price. The upgrade by Needham, a reputable financial firm, further validates the company's growth prospects, making it more attractive to investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100